Literature DB >> 15912968

FK-778 Astellas.

Mariana J Kaplan1.   

Abstract

Astellas, under license from sanofi-aventis, is developing the immunosuppressant compound FK-778 as a potential treatment for organ transplantation. By February 2005, phase II trials were ongoing both in the US and in Europe.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15912968

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  2 in total

Review 1.  Immunosuppressive potency of mechanistic target of rapamycin inhibitors in solid-organ transplantation.

Authors:  Alberto Baroja-Mazo; Beatriz Revilla-Nuin; Pablo Ramírez; José A Pons
Journal:  World J Transplant       Date:  2016-03-24

2.  A multicenter, randomized, double-blind study comparing different FK778 doses (manitimus) with tacrolimus and steroids vs. MMF with tacrolimus and steroids in renal transplantation.

Authors:  Zbigniew Wlodarczyk; Yves Vanrenterghem; Bernhard K Krämer; Jean-Paul Squifflet; Marek Ostrowski
Journal:  BMC Nephrol       Date:  2012-07-26       Impact factor: 2.388
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.